Market Closed -
OTC Markets
03:57:54 2024-07-09 pm EDT
|
5-day change
|
1st Jan Change
|
0.062
USD
|
-3.12%
|
|
-31.11%
|
-96.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
148.4
|
635.7
|
469.5
|
53.48
|
59.93
|
2.168
|
-
|
Enterprise Value (EV)
1 |
148.4
|
635.7
|
469.5
|
53.48
|
59.93
|
2.168
|
2.168
|
P/E ratio
|
-4.41
x
|
-15.6
x
|
-5.83
x
|
-0.46
x
|
-0.57
x
|
-0.03
x
|
-0.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
44.1
x
|
108
x
|
39.7
x
|
3.68
x
|
3.92
x
|
0.13
x
|
0.12
x
|
EV / Revenue
|
44.1
x
|
108
x
|
39.7
x
|
3.68
x
|
3.92
x
|
0.13
x
|
0.12
x
|
EV / EBITDA
|
-8,469,838
x
|
-18,264,854
x
|
-6,145,623
x
|
-458,934
x
|
-587,993
x
|
-
|
-
|
EV / FCF
|
-
|
-20,829,403
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,964
|
19,595
|
29,717
|
30,215
|
34,243
|
34,963
|
-
|
Reference price
2 |
12.40
|
32.44
|
15.80
|
1.770
|
1.750
|
0.0620
|
0.0620
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
3.364
|
5.885
|
11.84
|
14.52
|
15.3
|
16.2
|
17.4
|
EBITDA
|
-17.52
|
-34.8
|
-76.4
|
-116.5
|
-101.9
|
-
|
-
|
EBIT
1 |
-17.6
|
-35.29
|
-77.4
|
-118.2
|
-103.7
|
-76.31
|
-74.42
|
Operating Margin
|
-523.34%
|
-599.64%
|
-653.81%
|
-813.92%
|
-678.21%
|
-471.08%
|
-427.71%
|
Earnings before Tax (EBT)
1 |
-
|
-35.25
|
-78.34
|
-116.7
|
-100.9
|
-74.32
|
-74.42
|
Net income
1 |
-19.69
|
-35.25
|
-78.34
|
-116.7
|
-100.9
|
-74.32
|
-74.42
|
Net margin
|
-585.29%
|
-598.96%
|
-661.72%
|
-803.71%
|
-659.57%
|
-458.78%
|
-427.71%
|
EPS
2 |
-2.810
|
-2.080
|
-2.710
|
-3.880
|
-3.090
|
-2.120
|
-2.080
|
Free Cash Flow
|
-
|
-30.52
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-518.57%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.165
|
3.718
|
4.233
|
3.573
|
2.994
|
3.477
|
3.98
|
3.915
|
3.924
|
3.845
|
3.946
|
4.186
|
4.202
|
4.234
|
4.276
|
EBITDA
|
-26.02
|
-29.82
|
-29.44
|
-28.84
|
-28.43
|
-31.58
|
-31.66
|
-19.36
|
-19.31
|
-20.02
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.36
|
-30.19
|
-29.83
|
-29.26
|
-28.88
|
-32.04
|
-32.13
|
-19.81
|
-19.75
|
-20.51
|
-18.59
|
-18.58
|
-18.63
|
-18.73
|
-18.6
|
Operating Margin
|
-832.83%
|
-812.02%
|
-704.8%
|
-818.95%
|
-964.56%
|
-921.63%
|
-807.34%
|
-506%
|
-503.36%
|
-533.37%
|
-471.13%
|
-444.02%
|
-443.41%
|
-442.33%
|
-435.01%
|
Earnings before Tax (EBT)
1 |
-26.05
|
-30.11
|
-29.58
|
-28.77
|
-28.22
|
-31.27
|
-31.36
|
-19.16
|
-19.09
|
-20.01
|
-18.09
|
-18.09
|
-18.13
|
-18.73
|
-18.6
|
Net income
1 |
-26.05
|
-30.11
|
-29.58
|
-28.77
|
-28.22
|
-31.27
|
-31.36
|
-19.16
|
-19.09
|
-20.01
|
-18.09
|
-18.09
|
-18.13
|
-18.73
|
-18.6
|
Net margin
|
-823.16%
|
-809.79%
|
-698.8%
|
-805.26%
|
-942.65%
|
-899.34%
|
-788.02%
|
-489.5%
|
-486.52%
|
-520.42%
|
-458.51%
|
-432.12%
|
-431.56%
|
-442.33%
|
-435.01%
|
EPS
2 |
-0.8800
|
-1.010
|
-0.9900
|
-0.9600
|
-0.9300
|
-1.020
|
-0.9900
|
-0.5700
|
-0.5400
|
-0.5800
|
-0.5200
|
-0.5200
|
-0.5100
|
-0.5300
|
-0.5200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/3/22
|
8/8/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/29/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-30.5
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
1.83
|
2.72
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
31.16%
|
22.98%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/1/22
|
3/2/23
|
2/29/24
|
-
|
-
|
Last Close Price
0.062
USD Average target price
1.5
USD Spread / Average Target +2,319.35% Consensus |
1st Jan change
|
Capi.
|
---|
| -96.46% | 2.17M | | -9.24% | 11.66B | | -23.11% | 6.5B | | +6.07% | 5.7B | | +25.32% | 5.39B | | -24.21% | 3.45B | | +4.96% | 2.52B | | +31.87% | 2.28B | | -67.39% | 2.18B | | -13.25% | 2.16B |
Diagnostic & Testing Substances
|